Please assess the completion status of the following clinical trial:

Trial Title: Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed non-small cell lung cancer, including squamous cell carcinomas, adenocarcinomas and non-neuroendocrine large cell carcinomas~* Patients with advanced stages of NSCLC who are candidates to first-line platinum-based doublet chemotherapy~* Measurable disease by RECIST 1.1~* Age ≥ 18 years.~* Performance status 0-2.~* Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion):~  * White blood cells (WBC) ≥ 3.0 \* 10\^9/l or neutrophils (ANC) ≥ 1.5 \* 10\^9/l~ * Platelet count ≥ 100 \* 10\^9/l~ * Hemoglobin ≥ 6 mmol/l~ * Serum bilirubin \< 2.0 \* upper level of normal (ULN)~ * Serum transaminase ≤ 2.5 \* ULN~ * Serum creatinine ≤ 1.5 ULN~* Written and orally informed consent.~Exclusion Criteria:~* Other malignant diseases within 5 years prior to inclusion in the study, except curatively treated basal cell or squamous cell carcinoma of the skin and other types of cancer with minimal risk of recurrence.~* Other experimental therapy or participation in another clinical trial within 28 days prior to treatment initiation.~* Patients who have received prior chemotherapy for NSCLC~* Patients with NSCLC who are candidates to neoadjuvant chemotherapy or curative chemoradiotherapy~* Underlying disease not adequately treated (diabetes, cardiac disease)~* Allergy to the active substance or any of the auxiliary agents~* Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at screening is mandatory.~* Fertile patients not willing to use effective methods of contraception during treatment and for 6 months after the end of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Performance status 0-1, Arm A (Type: EXPERIMENTAL): Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Tocotrienol 300 mg x 3 daily until progression.
- Performance status 0-1, Arm B (Type: EXPERIMENTAL): Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Placebo 1 capsule x 3 daily until progression.
- Performance status 2, Arm A (Type: EXPERIMENTAL): Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Tocotrienol 300 mg x 3 daily until progression
- Performance status 2, Arm B (Type: EXPERIMENTAL): Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Placebo 1 capsule x 3 daily until progression

Based on this trial design, predict the completion outcome and termination type (if applicable).